miR-21 is targeted by omega-3 polyunsaturated fatty acid to regulate breast tumor CSF-1 expression

Carcinogenesis

Volumn 33, Issue 10, 2012, Pages 1897-1908

  Mandal, Chandi Charan ^a   Ghosh Choudhury, Triparna ^a,c   Dey, Nirmalya ^a   Choudhury, Goutam Ghosh ^a,b   Ghosh Choudhury, Nandini ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; DOCOSAHEXAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA 21; OMEGA 3 FATTY ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SYNAPTOTAGMIN I;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOCOSAHEXAENOIC ACIDS; FATTY ACIDS, OMEGA-3; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MICE; MICE, NUDE; MICRORNAS; PTEN PHOSPHOHYDROLASE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84867290416     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs198     Document Type: Article

References (57)

1. Stanley, E. R. et al. (1983) CSF-1-a mononuclear phagocyte lineage-specific hemopoietic growth factor. J. Cell. Biochem., 21, 151-159.
2. Lin, E. Y. et al. (2002) The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J. Mammary Gland Biol. Neoplasia, 7, 147-162.
3. Kodama, H. et al. (1991) Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J. Exp. Med., 173, 1291-1294.
4. Grey, A. et al. (2000) Evidence for a functional association between phosphatidylinositol 3-kinase and c-src in the spreading response of osteoclasts to colony-stimulating factor-1. Endocrinology, 141, 2129-2138.
5. Roussel, M.F. et al. (2003) Oncogenic potential of the c-FMS proto-oncogene (CSF-1 receptor). Cell Cycle, 2, 5-6.
6. Kacinski, B.M. (1997) CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol. Reprod. Dev., 46, 71-74.
7. Sapi, E. et al. (1996) Independent regulation of invasion and anchorageindependent growth by different autophosphorylation sites of the macrophage colony-stimulating factor 1 receptor. Cancer Res., 56, 5704-5712.
8. Kacinski, B.M. (1995) CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann. Med., 27, 79-85.
9. Scholl, S.M. et al. (1994) Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J. Natl Cancer Inst., 86, 120-126.
10. Couzin, J. (2008) MicroRNAs make big impression in disease after disease. Science, 319, 1782-1784.
11. O'Day, E. et al. (2010) MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res., 12, 201.
12. Verghese, E.T. et al. (2008) Small is beautiful: microRNAs and breast cancer-where are we now? J. Pathol., 215, 214-221.
13. Iorio, M.V. et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res., 65, 7065-7070.
14. Qian, B. et al. (2009) High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res. Treat., 117, 131-140.
15. Fujita, S. et al. (2008) miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J. Mol. Biol., 378, 492-504.
16. Fabian, M.R. et al. (2010) Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem., 79, 351-379.
17. Kelsey, J.L. et al. (1993) Breast cancer: magnitude of the problem and descriptive epidemiology. Epidemiol. Rev., 15, 7-16.
18. Lands, W.E. et al. (1990) Changing dietary patterns. Am. J. Clin. Nutr., 51, 991-993.
19. Chajes, V. et al. (1995) Influence of n-3 fatty acids on the growth of human breast cancer cells in vitro: relationship to peroxides and vitamin-E. Breast Cancer Res. Treat., 34, 199-212.
20. Grammatikos, S.I. et al. (1994) n-3 and n-6 fatty acid processing and growth effects in neoplastic and non-cancerous human mammary epithelial cell lines. Br. J. Cancer, 70, 219-227.
21. Rose, D.P. et al. (1999) Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol. Ther., 83, 217-244.
22. Mandal, C.C. et al. (2010) Fish oil prevents breast cancer cell metastasis to bone. Biochem. Biophys. Res. Commun., 402, 602-607.
23. Mandal, C.C. et al. (2011) Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J. Biol. Chem., 286, 11314-11327.
24. Ghosh-Choudhury, T. et al. (2009) Fish oil targets PTEN to regulate NFkappaB for downregulation of anti-apoptotic genes in breast tumor growth. Breast Cancer Res. Treat., 118, 213-228.
25. Dey, N. et al. (2011) MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. J. Biol. Chem., 286, 25586-25603.
26. Zhou, R. et al. (2010) Binding of NF-kappaB p65 subunit to the promoter elements is involved in LPS-induced transactivation of miRNA genes in human biliary epithelial cells. Nucleic Acids Res., 38, 3222-3232.
27. Ghosh-Choudhury, N. et al. (2002) Requirement of BMP-2-induced phosphatidylinositol 3-kinase and Akt serine/threonine kinase in osteoblast differentiation and Smad-dependent BMP-2 gene transcription. J. Biol. Chem., 277, 33361-33368.
28. Mahimainathan, L. et al. (2004) Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J. Biol. Chem., 279, 15258-15268.
29. Ghosh-Choudhury, N. et al. (2006) Concerted action of Smad and CREBbinding protein regulates bone morphogenetic protein-2-stimulated osteoblastic colony-stimulating factor-1 expression. J. Biol. Chem., 281, 20160-20170.
30. Ghosh-Choudhury, N. et al. (2010) Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal., 22, 749-758.
31. Mancino, A.T. et al. (2001) Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J. Surg. Res., 100, 18-24.
32. Hiraga, T. et al. (2001) The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res., 61, 4418-4424.
33. Mundy, G.R. (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer, 2, 584-593.
34. Salmena, L. et al. (2008) Tenets of PTEN tumor suppression. Cell, 133, 403-414.
35. Ebert, M.S. et al. (2007) MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods, 4, 721-726.
36. Scholl, S.M. et al. (1993) Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metastasis? Mol. Carcinog., 7, 207-211.
37. Kerbel, R.S. (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis, 21, 505-515.
38. Lin, E.Y. et al. (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med., 193, 727-740.
39. Baselga, J. (2011) Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist, 16 (suppl. 1), 12-19.
40. Bachman, K.E. et al. (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther., 3, 772-775.
41. Kang, S. et al. (2006) Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc. Natl Acad. Sci. USA, 103, 1289-1294.
42. Zhao, J.J. et al. (2006) PI3 kinases in cancer: from oncogene artifact to leading cancer target. Sci. STKE, 2006, pe52.
43. Stiles, B. et al. (2004) PTENless means more. Dev. Biol., 273, 175-184.
44. Saal, L.H. et al. (2008) Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat. Genet., 40, 102-107.
45. Stambolic, V. et al. (2000) High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res., 60, 3605-3611.
46. Li, G. et al. (2002) Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development, 129, 4159-4170.
47. Perez-Tenorio, G. et al. (2007) PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin. Cancer Res., 13, 3577-3584.
48. Leslie, N.R. et al. (2011) Non-genomic loss of PTEN function in cancer: not in my genes. Trends Pharmacol. Sci., 32, 131-140.
49. He, L. (2010) Posttranscriptional regulation of PTEN dosage by noncoding RNAs. Sci. Signal., 3, pe39.
50. Walter, B.A. et al. (2011) miR-21 expression in pregnancy-associated breast cancer: a possible marker of poor prognosis. J. Cancer, 2, 67-75.
51. Wang, Z.X. et al. (2011) MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN. Arch. Med. Res., 42, 281-290.
52. Gong, C. et al. (2011) Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J. Biol. Chem., 286, 19127-19137.
53. Wickramasinghe, N.S. et al. (2009) Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res., 37, 2584-2595.
54. Bhat-Nakshatri, P. et al. (2009) Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res., 37, 4850-4861.
55. Lu, I.F. et al. (2010) Docosahexaenoic acid induces proteasome-dependent degradation of estrogen receptor alpha and inhibits the downstream signaling target in MCF-7 breast cancer cells. J. Nutr. Biochem., 21, 512-517.
56. Trotman, L.C. et al. (2003) Pten dose dictates cancer progression in the prostate. PLoS Biol., 1, E59.
57. Alimonti, A. et al. (2010) Subtle variations in Pten dose determine cancer susceptibility. Nat, Genet, 42, 454-458.